

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/879,320	06/12/2001	Ajay Hasmukhlal Upadhyay	RD 01022	5176
7	590 01/26/2005		EXAMINER	
KEVIN E. MC VEIGH			CHANNAVAJJALA, LAKSHMI SARADA	
RHODIA INC. 259 PROSPECT PLAINS ROAD			ART UNIT	PAPER NUMBER
CRANBURY, NJ 08512			1615	

DATE MAILED: 01/26/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/879,320	UPADHYAY, AJAY HAS	SMUKHLA		
		Examiner	Art Unit	- · · ·		
		Lakshmi S Channavajjala	1615			
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet with the c	orrespondence address	1		
THE I - Exter after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a replayer of the provision of the		nely filed s will be considered timely. the mailing date of this communic D (35 U.S.C. § 133).	cation.		
Status				•		
1)🖂	Responsive to communication(s) filed on 120	<u>October 2004</u> .				
2a) <u></u> □	This action is FINAL . 2b)⊠ Thi	s action is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims			•		
5)□ 6)⊠ 7)□	Claim(s) 1-3,6-8,31 and 33-36 is/are pending 4a) Of the above claim(s) is/are withdra Claim(s) is/are allowed. Claim(s) 1-3,6-8,31 and 33-36 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	awn from consideration.				
Applicati	on Papers					
9)[The specification is objected to by the Examin	er.				
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
	Applicant may not request that any objection to the	*··	• •			
11)	Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the E	, , , , ,		• •		
Priority u	ınder 35 U.S.C. § 119					
12) <u> </u>	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureasee the attached detailed Office action for a list	nts have been received. Its have been received in Applicationity documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage	.		
Attachmen		_		•		
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
3) 🔲 Inforr	e of Dransperson's Patent Drawing Review (P10-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 r No(s)/Mail Date		atent Application (PTO-152)			

DETAILED ACTION

Receipt of amendment and remarks of 10-12-04 is acknowledged.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10-12-04 has been entered.

Claims 1-4, 6-8, 31 and 33-36 are pending in the instant application.

Claim Rejections - 35 USC § 103

Claims 1-4, 6-8, 31 and 33-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,798,725 to Patel (Patel).

Patel teaches a pharmaceutical composition for oral administration comprising a particulate mixture of an active drug, polyvinylpyrrolidone and a carboxyvinyl polymer (abstract, col. 6, lines 61-68). The particulate mixture of Patel is a flowable and is composed of particles that have a tendency to moderately adhere and yet move (paragraph bridging col. 2-3). Patel teaches PVP in an amount of 5% to 96% (col. 4, lines 10-21), and active agent in an amount of 0.01% to 90% (col. 6, lines 55-60). Patel also teaches that the particles have a size such that they pass through 60 mesh, which accordingly to the instant specification is 250microns and thus is within the claimed range. According to claim 1, <30% of the particles

have a size greater than 425 microns and >80% of the particles have a size greater than 45 microns. In other words, the size of the instant particles is between 45 and 425 microns, which includes 250 microns. Example 7 of Patel is directed to a composition of particulate mixture of guaifenesin together with PVP, talc, zinc stearate and Carbopol.

Patel fails to teach the following claim limitations: exact percentages of the particles of specific sizes, agglomerated mixture, percentages of the amounts of guaifenesin, specific solubilizer maltodextrin and the claimed flow rate. However, Patel teaches a particulate mixture of the same active ingredient and binder as claimed and the particle sizes used by Patel, as explained above, in the same range as claimed. Patel also suggests high amounts of active agent, as high as 90%. Further, the invention of Patel is also directed to a particulate and yet flowable composition (col. 10, lines 37-49), so as to obtain a sustained release of the drug. Furthermore, Patel also suggests addition of the pharmaceutical excipients such as silicon dioxide, stearic acid, talc and other conventional additives (col. 7). Therefore, it would have been obvious for one of an ordinary skill in the art at the time of the instant invention to optimize the amounts of particulate guaifenesin, PVP and other additives, choose the particle sizes and the excipients in the composition of Patel, so as to achieve the desired flow rate of the particle mixture (of active and the excipients) and thus achieve a desired release pattern.

Response to Arguments

Applicant's arguments with respect to claims 1-4, 6-8, 31 and 33-36 have been considered but are most in view of the new ground(s) of rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lakshmi S Channavajjala whose telephone number is 571-272-0591. The examiner can normally be reached on 7.30 AM -4.00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Lakshmi S Channavajjala

Examiner

Art Unit 1615

January 21, 2005